Olaratumab for STS Disappoints in Phase III.
Two years after receiving accelerated approval from the FDA as first-line therapy with doxorubicin for patients with advanced or inoperable soft-tissue sarcoma, the anti-PDGFRα antibody olaratumab's potential has not held up in a required phase III study. The combination yielded no significant difference in median overall survival compared with doxorubicin alone, prompting the company to stop promoting olaratumab.